Annual Cash & Cash Equivalents
$4.54 M
-$185.00 K-3.91%
December 31, 2023
Summary
- As of February 7, 2025, DMAC annual cash & cash equivalents is $4.54 million, with the most recent change of -$185.00 thousand (-3.91%) on December 31, 2023.
- During the last 3 years, DMAC annual cash & cash equivalents has fallen by -$2.87 million (-38.68%).
- DMAC annual cash & cash equivalents is now -73.00% below its all-time high of $16.82 million, reached on December 31, 2018.
Performance
DMAC Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$4.13 M
-$9.93 M-70.61%
September 30, 2024
Summary
- As of February 7, 2025, DMAC quarterly cash and cash equivalents is $4.13 million, with the most recent change of -$9.93 million (-70.61%) on September 30, 2024.
- Over the past year, DMAC quarterly cash and cash equivalents has increased by +$1.90 million (+85.22%).
- DMAC quarterly cash and cash equivalents is now -75.43% below its all-time high of $16.82 million, reached on December 31, 2018.
Performance
DMAC Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
DMAC Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -3.9% | +85.2% |
| 3 y3 years | -38.7% | -74.5% |
| 5 y5 years | -73.0% | -74.5% |
DMAC Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -3.9% | at low | -70.6% | +97.1% |
| 5 y | 5-year | -38.7% | +17.0% | -74.5% | +97.1% |
| alltime | all time | -73.0% | >+9999.0% | -75.4% | +2852.9% |
DiaMedica Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $4.13 M(-70.6%) |
| Jun 2024 | - | $14.07 M(+570.8%) |
| Mar 2024 | - | $2.10 M(-53.8%) |
| Dec 2023 | $4.54 M(-3.9%) | $4.54 M(+103.5%) |
| Sep 2023 | - | $2.23 M(-61.8%) |
| Jun 2023 | - | $5.84 M(+172.0%) |
| Mar 2023 | - | $2.15 M(-54.6%) |
| Dec 2022 | $4.73 M(+0.4%) | $4.73 M(+70.6%) |
| Sep 2022 | - | $2.77 M(-9.5%) |
| Jun 2022 | - | $3.06 M(+1.0%) |
| Mar 2022 | - | $3.03 M(-35.6%) |
| Dec 2021 | $4.71 M(-36.5%) | $4.71 M(-71.0%) |
| Sep 2021 | - | $16.22 M(+628.0%) |
| Jun 2021 | - | $2.23 M(-33.1%) |
| Mar 2021 | - | $3.33 M(-55.1%) |
| Dec 2020 | $7.41 M(+90.8%) | $7.41 M(-24.4%) |
| Sep 2020 | - | $9.80 M(+97.7%) |
| Jun 2020 | - | $4.96 M(+50.2%) |
| Mar 2020 | - | $3.30 M(-15.0%) |
| Dec 2019 | $3.88 M(-76.9%) | $3.88 M(-18.1%) |
| Sep 2019 | - | $4.74 M(+59.4%) |
| Jun 2019 | - | $2.97 M(+7.8%) |
| Mar 2019 | - | $2.76 M(-83.6%) |
| Dec 2018 | $16.82 M(+1143.4%) | $16.82 M(+331.3%) |
| Sep 2018 | - | $3.90 M(-31.1%) |
| Jun 2018 | - | $5.66 M(-15.7%) |
| Mar 2018 | - | $6.72 M(+396.6%) |
| Dec 2017 | $1.35 M(-22.1%) | $1.35 M(+57.7%) |
| Sep 2017 | - | $857.70 K(-43.9%) |
| Jun 2017 | - | $1.53 M(+63.0%) |
| Mar 2017 | - | $938.50 K(-45.9%) |
| Dec 2016 | $1.74 M(+945.2%) | $1.74 M(-41.4%) |
| Sep 2016 | - | $2.96 M(+711.6%) |
| Jun 2016 | - | $365.20 K(+9.5%) |
| Mar 2016 | - | $333.40 K(+100.7%) |
| Dec 2015 | $166.10 K | $166.10 K(+18.6%) |
| Sep 2015 | - | $140.00 K(-69.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2015 | - | $458.20 K(+71.0%) |
| Mar 2015 | - | $267.90 K(+31.4%) |
| Dec 2014 | $203.90 K(-91.9%) | $203.90 K(-58.1%) |
| Sep 2014 | - | $486.50 K(-61.1%) |
| Jun 2014 | - | $1.25 M(-15.1%) |
| Mar 2014 | - | $1.47 M(-41.7%) |
| Dec 2013 | $2.52 M(+7.8%) | $2.52 M(+136.7%) |
| Sep 2013 | - | $1.06 M(-48.8%) |
| Jun 2013 | - | $2.08 M(-52.1%) |
| Mar 2013 | - | $4.34 M(+85.4%) |
| Dec 2012 | $2.34 M(-11.8%) | $2.34 M(-39.8%) |
| Sep 2012 | - | $3.89 M(-0.8%) |
| Jun 2012 | - | $3.92 M(+88.8%) |
| Mar 2012 | - | $2.07 M(-21.8%) |
| Dec 2011 | $2.65 M(-6.5%) | $2.65 M(-31.2%) |
| Sep 2011 | - | $3.85 M(+117.1%) |
| Jun 2011 | - | $1.77 M(-26.2%) |
| Mar 2011 | - | $2.40 M(-15.3%) |
| Dec 2010 | $2.84 M(+350.6%) | $2.84 M(+489.2%) |
| Sep 2010 | - | $481.50 K(+209.2%) |
| Jun 2010 | - | $155.70 K(-53.9%) |
| Mar 2010 | - | $337.90 K(-46.3%) |
| Dec 2009 | $629.50 K(-74.5%) | $629.50 K(-41.7%) |
| Sep 2009 | - | $1.08 M(-25.2%) |
| Jun 2009 | - | $1.44 M(-23.7%) |
| Mar 2009 | - | $1.89 M(-23.3%) |
| Dec 2008 | $2.47 M(-29.5%) | $2.47 M(-22.0%) |
| Sep 2008 | - | $3.16 M(+16.8%) |
| Jun 2008 | - | $2.71 M(-19.1%) |
| Mar 2008 | - | $3.35 M(-4.4%) |
| Dec 2007 | $3.50 M(+1198.8%) | $3.50 M(-6.4%) |
| Sep 2007 | - | $3.74 M(-11.7%) |
| Jun 2007 | - | $4.24 M(+0.2%) |
| Mar 2007 | - | $4.23 M(+1468.8%) |
| Dec 2006 | $269.60 K(-1.9%) | $269.60 K(+36.9%) |
| Sep 2006 | - | $197.00 K(-28.3%) |
| Dec 2005 | $274.80 K(+3515.8%) | $274.80 K |
| Dec 2004 | $7600.00 | - |
FAQ
- What is DiaMedica Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for DiaMedica Therapeutics?
- What is DiaMedica Therapeutics annual cash & cash equivalents year-on-year change?
- What is DiaMedica Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for DiaMedica Therapeutics?
- What is DiaMedica Therapeutics quarterly cash and cash equivalents year-on-year change?
What is DiaMedica Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of DMAC is $4.54 M
What is the all time high annual cash & cash equivalents for DiaMedica Therapeutics?
DiaMedica Therapeutics all-time high annual cash & cash equivalents is $16.82 M
What is DiaMedica Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, DMAC annual cash & cash equivalents has changed by -$185.00 K (-3.91%)
What is DiaMedica Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of DMAC is $4.13 M
What is the all time high quarterly cash and cash equivalents for DiaMedica Therapeutics?
DiaMedica Therapeutics all-time high quarterly cash and cash equivalents is $16.82 M
What is DiaMedica Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, DMAC quarterly cash and cash equivalents has changed by +$1.90 M (+85.22%)